NCT05365178进行中（未招募）3 期
A Randomized, Double-blind, Parallel-controlled Phase III Trial Evaluating the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated HR-positive, HER2-negative Advanced Breast Cancer
适应症
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 入组人数
- 432
- 试验地点
- 155
- 主要终点
- Progression-free survival as assessed by the investigator
研究概览
简要总结
A randomized, double-blind, parallel-controlled, multicenter trial design was used in this study. Subjects who meet the criteria will be randomly divided into 2:1 groups to receive TBQ3616 capsule combined with Fulvestrant injection (experimental group) or placebo capsule combined with fulvestrant (control group). A total of 428 subjects were required.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Subjects voluntarily participate in this study and sign informed consent with good compliance;
- •Age: 18-75 years (when signing the informed consent); an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1; Is expected to survive more than 3 months;
- •Postmenopausal or premenopausal/perimenopausal women；
- •Patients with HR-positive or HER2-negative breast cancer confirmed by pathological examination with evidence of local lesion recurrence or distant metastasis, not suitable for the surgery or radiotherapy for the purpose of cure, and there are no clinical indications of chemotherapy；
- •Have a measurable lesion (RECIST (Response Evaluation Criteria In Solid Tumors) 1.1 criteria), or have only bone metastases；
- •The main organs function well and meet the following standards：
- •Routine blood examination should meet the following criteria: (No blood transfusion and no hematopoietic stimulation drugs within 7 days before screening)
- •Hemoglobin (HB) ≥100 g/L;
- •Absolute value of neutrophils (NEUT) ≥ 1.5×109/L;
- •Platelet count (PLT) ≥ 90 ×109/L.
- •Biochemical blood tests shall meet the following criteria：
- •Total bilirubin (TBIL) ≤ 1.5 times normal upper limit (ULN);
- •Alanine transferase (ALT) and aspartate transferase (AST) ≤ 2.5×ULN; ALT and AST≤ 3×ULN for patients with liver metastasis;
- •Serum creatinine (Cr) ≤ 1.5×ULN, or creatinine clearance (Ccr) ≥ 60 mL /min；
- •Coagulation function tests shall meet the following criteria：
- •(a) Prothrombin time (PT), activated partial thrombin time (APTT), international standardized
- •Color doppler echocardiography: Left ventricular ejection fraction (LVEF) ≥50%；
- •Female subjects within reproductive age should agree to use contraceptive methods (such as intrauterine devices, birth control pills or condoms) from participating the study to 6 months after the end of the study; Serum pregnancy test result should be negative within 7 days prior to study enrollment and must be non-lactating subjects.
排除标准
- •Associated diseases and history：
- •The presence or current co-occurrence of other malignant tumors within 5 years, except ured cervical carcinoma in situ, non-melanoma skin cancer, and superficial bladder tumors [Ta (non-invasive tumor), Tis (carcinoma in situ), and T1 (tumor infiltrating basal membrane)];
- •Multiple factors affecting oral and drug absorption (such as inability to swallow, post-gastrointestinal resection, ulcerative colitis, symptomatic/inflammatory bowel disease, chronic diarrhea and intestinal obstruction);
- •Patients with a history of severe pneumonia such as interstitial lung disease;
- •Unrelieved toxicity higher than GRADE 1 Common Terminology Criteria for Adverse Events (CTCAE) due to any previous anti-tumor treatment, hair loss is not included;
- •Major surgery or significant traumatic injury within 28 days prior to randomization;
- •Long-term unhealed wounds, ulcers or fractures;
- •Occurrence of arteriovenous/venous thrombosis events within 6 months, such as cerebrovascular accident (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis and pulmonary embolism, etc.;
- •History of psychotropic drug abuse and can't get rid of it or with mental disorders;
- •Subject with any severe and/or uncontrolled disease, including：
- •Arrhythmias requiring treatment with grade≥2 myocardial ischemia, myocardial infarction, and congestive heart failure (NYHA(New York Heart Association) classification) within 6 months prior to study enrollment (including qtc≥480ms during screening period); And uncontrolled high blood pressure;
- •Active or uncontrolled severe infection (≥CTCAE grade 2 infection) or unexplained fever > 38.5℃ within 28 days prior to randomization;
- •Decompensated cirrhosis (Child-Pugh liver function score B or C), active hepatitis ;
- •Patients with renal failure requiring hemodialysis or peritoneal dialysis;
- •A history of immunodeficiency, including HIV ( Human Immunodeficiency Virus) positive or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation or hematopoietic stem cell transplantation;
- •Tumor-related symptoms and treatment；
- •Visceral crisis exists;
- •Severe bone injury due to bone metastasis of tumor;
- •Received radiotherapy (except palliative radiotherapy for non-target lesions) and other anti-tumor therapies (the washout period was calculated from the end of the last treatment) within 2 weeks prior to randomization;
- •Prior medical treatment with fulvestrant, everolimus or CDK4/6 inhibitor;
- •The presence of clinically uncontrolled pleural, ascites and pericardial effusion requiring repeated drainage or medical intervention (14 days prior to randomization);
- •Known allergy to fulvestrant, Luteal Hormone Releasing Hormone (LHRH) agonists (e.g. Goserelin), TQB3616/ placebo or any supplement;
- •History of live attenuated vaccine vaccination within 28 days prior to randomization or planned live attenuated vaccine vaccination during the study period;
- •Participated in clinical trials of other antitumor drugs within 4 weeks pior to randomization;
- •With other serious physical or mental diseases or abnormal laboratory tests that may increase the risk of study participation or interfere with the study results, or unsuitable for the study for other reasons considered by investigators.
研究组 & 干预措施
TQB3616 capsule + Fulvestrant injection
Experimental
TQB3616 capsule:
180mg was given orally with meals or within 2 hours after meals, once a day， every 28 days for a cycle.
Fulvestrant injection:
500mg intramuscular injection was administered on day 1, every 28 days for a cycle, for the first cycle, was administered on day 1 and day 15
干预措施: TQB3616 capsule (Drug)
TQB3616 capsule + Fulvestrant injection
Experimental
TQB3616 capsule:
180mg was given orally with meals or within 2 hours after meals, once a day， every 28 days for a cycle.
Fulvestrant injection:
500mg intramuscular injection was administered on day 1, every 28 days for a cycle, for the first cycle, was administered on day 1 and day 15
干预措施: Fulvestrant injection (Drug)
Placebo capsule + Fulvestrant injection
Placebo Comparator
Placebo capsules:
0mg was given orally with meals or within 2 hours after meals, once a day, every 28 days for a cycle.
Fulvestrant injection:
500mg intramuscular injection was administered on day 1, every 28 days for a cycle, for the first cycle, was administered on day 1 and day 15
干预措施: Placebo (Drug)
Placebo capsule + Fulvestrant injection
Placebo Comparator
Placebo capsules:
0mg was given orally with meals or within 2 hours after meals, once a day, every 28 days for a cycle.
Fulvestrant injection:
500mg intramuscular injection was administered on day 1, every 28 days for a cycle, for the first cycle, was administered on day 1 and day 15
干预措施: Fulvestrant injection (Drug)
结局指标
主要结局
Progression-free survival as assessed by the investigator
时间窗: Baseline up to progressive disease (PD)/die, about 25.8 months
The time from enrollment to the date of the first documentation of objective progression of disease or death due to any cause, whichever occurs first.
次要结局
- Objective Response Rate (ORR)(Baseline to CR/PR，about 1 year)
- Progression-free survival (PFS) by independent imaging assessment(Baseline up to PD/die, about 25.8 months)
- Duration of Overall Response (DOR)(CR/PR assessment, up to PD/die, about 20 months)
- The European Organization for Research and Treatment of Cancer Quality of Life questionnaire(Baseline to the end of the study, about 3 years)
- Incidence of adverse events (AEs), serious adverse events (SAEs) and treatment-related adverse events (TEAEs).(Baseline to the end of the study, about 3 years)
- Overall survival(Baseline up to die, about 36months)
- 3-Year Overall Survival (OS)(Baseline to 3 years)
- Clinical Benefit Rate(CBR)(Baseline to CR/PR/SD，about 1 year)
研究者
研究点 (155)
Loading locations...
相似试验
已完成
3 期
Bio-equivalence Study Comparing Permethrin Cream, 5% With Elimite in Patients With Active Scabies.ScabiesNCT02978508Mayne Pharma International Pty Ltd140
已完成
2 期
Efficacy and Safety of Vandetanib (ZD6474) in Patients With Metastatic Papillary or Follicular Thyroid CancerThyroid NeoplasmsNCT00537095Genzyme, a Sanofi Company164
尚未招募
不适用
Hydrogen-Oxygen Generator With Nebulizer for Adjuvant Treatment of Novel Coronavirus Disease 2019 (COVID-19)Covid19Hydrogen-oxygen GasAMS-H-03NCT05770206Guangzhou Institute of Respiratory Disease218
尚未招募
2 期
Study of the KPCXM18 Injection for Treatment of Acute Ischemic StrokeAcute Ischemic StrokeNCT05745311Kunming Pharmaceuticals, Inc.240
已完成
2 期
Phase II Clinical Trial to Evaluate the Efficacy and Safety of LPM3480392 Injection for Moderate to Severe Pain After Abdominal SurgeryPain, PostoperativeNCT06204120Luye Pharma Group Ltd.150